Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging

NCT04586816 · View on ClinicalTrials.gov ↗

Study Summary

Recent research has reported that the maple leaf extract exhibits anti-aging effects by inhibiting elastase activity, thereby preventing the breakdown of elastin and interfering with the formation of wrinkles. Red maple leaf extract contains phenolic compounds known as glucitol-core-containing gallotannins (GCGs) which help reduce the appearance of wrinkles and may decrease skin inflammation, dark spots and pigmentation. The objective of this study is to examine the effects of topical Maplifa on the cosmetic appearance of facial lines, redness and skin tone.

Interventions

  • COMBINATION_PRODUCT 1% red maple leaf extract in cream base
  • COMBINATION_PRODUCT 5% red maple leaf extract
  • COMBINATION_PRODUCT vehicle

Study Locations (1)

California

  • Integrative Skin Science and Research — Sacramento

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2019-09-10
Est. Completion 2020-01-15
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04586816

The ClinicalTrials.gov registry entry for NCT04586816 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integrative Skin Science and Research, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Photoaging appearing as the primary indexed condition, and to 3 interventions — of which 1% red maple leaf extract in cream base is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04586816 reports 1 study location spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04586816 about?

NCT04586816 is a clinical study titled "Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging". Recent research has reported that the maple leaf extract exhibits anti-aging effects by inhibiting elastase activity, thereby preventing the breakdown of elastin and interfering with the formation of wrinkles. Red maple leaf extract contains phenolic compounds known as glucitol-core-containing gallo...

What is the current status of trial NCT04586816?

This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2019-09-10. Estimated completion is 2020-01-15.

What conditions does trial NCT04586816 study?

This clinical trial studies the following conditions: Photoaging, Hyperpigmentation, Rhytides. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04586816?

The interventions under investigation include: 1% red maple leaf extract in cream base (COMBINATION_PRODUCT), 5% red maple leaf extract (COMBINATION_PRODUCT), vehicle (COMBINATION_PRODUCT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04586816?

This trial is sponsored by Integrative Skin Science and Research, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04586816 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial